Cellworks offers precision biosimulation platforms that model disease biology and drug responses to accelerate drug development and improve patient outcomes. By integrating genomics, clinical data, and computational modeling, their tools can predict the benefit of combining chemotherapy with immunotherapy in metastatic non‑small cell lung cancer, helping clinicians and researchers make data‑driven treatment decisions. The platform supports end‑to‑end simulation workflows for pharmaceutical and biotech teams.
Funding
$15.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug development for complex cancers often relies on limited preclinical data and trial-and-error approaches, leading to high costs, long timelines, and suboptimal patient outcomes. Clinicians also lack reliable tools to predict how combining therapies such as chemotherapy and immunotherapy will affect individual patients with metastatic non‑small cell lung cancer.
Solution
Cellworks offers a precision biosimulation platform that uses computational models of disease biology integrated with genomics data to forecast therapeutic responses. The system simulates the molecular impact of combining chemotherapy with immunotherapy in metastatic NSCLC, generating quantitative predictions of clinical benefit. Researchers can explore virtual trial scenarios to prioritize promising regimens, while clinicians receive decision-support insights to tailor treatment plans. By providing detailed, data‑driven biosimulation outputs, the platform aims to accelerate drug development cycles and improve the precision of patient care.
Target Audience
Primary users are pharmaceutical R&D teams developing oncology therapies and oncologists/clinical researchers seeking data‑driven guidance for treatment selection in metastatic non‑small cell lung cancer.
Features
- Integrative genomics engine that incorporates patient-specific molecular profiles into disease models
- Computational simulation of combined chemotherapy and immunotherapy effects on tumor biology
- Predictive analytics dashboards delivering quantitative benefit estimates for metastatic NSCLC
- Virtual trial environment enabling rapid hypothesis testing and regimen optimization
- Cloud‑based platform with secure data handling and API access for seamless integration into research pipelines